title: Sex differences between CRF1 receptor deficient mice following naloxone-precipitated morphine withdrawal in a conditioned place aversion paradigm: implication of HPA axis.
abstract: BACKGROUND
  Extinction period of positive affective memory of drug taking and negative affective memory of drug withdrawal, as well as the different response of men and women might be important for the clinical treatment of drug addiction. We investigate the role of corticotropin releasing factor receptor type one (CRF1R) and the different response of male and female mice in the expression and extinction of the aversive memory.
  
  
  RESULTS
  We used genetically engineered male and female mice lacking functional CRF1R. The animals were rendered dependent on morphine by intraperitoneally injection of increasing doses of morphine (10-60 mg/kg). Negative state associated with naloxone (1 mg/kg s.c.)-precipitated morphine withdrawal was examined by using conditioned place aversion (CPA) paradigm. No sex differences for CPA expression were found in wild-type (n = 29) or CRF1R knockout (KO) mice (n = 29). However, CRF1R KO mice presented less aversion score than wild-type mice, suggesting that CRF1R KO mice were less responsive than wild-type to continuous associations between drug administration and environmental stimuli. In addition, CPA extinction was delayed in wild-type and CRF1R KO male mice compared with females of both genotypes. The genetic disruption of the CRF1R pathway decreased the period of extinction in males and females suggesting that CRF/CRF1R is implicated in the duration of aversive memory. Our results also showed that the increase in adrenocorticotropic hormone (ACTH) levels observed in wild-type (n = 11) mice after CPA expression, were attenuated in CRF1R KO mice (n = 10). In addition, ACTH returned to the baseline levels in males and females once CPA extinction was finished.
  
  
  CONCLUSIONS
  These results suggest that, at least, CPA expression is partially due to an increase in plasma ACTH levels, through activation of CRF1R, which can return when CPA extinction is finished.
authors.affiliation: Department of Pharmacology, School of Medicine, University of Murcia, Murcia, Spain.
authors.forename: Juan-Antonio
authors.initials: JA
authors.lastname: García-Carmona
authors.affiliation: Group of Inflammation, FFIS-University Hospital V. A., Murcia, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Baroja-Mazo
authors.affiliation: Department of Pharmacology, School of Medicine, University of Murcia, Murcia, Spain.
authors.forename: María-Victoria
authors.initials: MV
authors.lastname: Milanés
authors.affiliation: Department of Pharmacology, School of Medicine, University of Murcia, Murcia, Spain.
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Laorden
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003345:Corticosterone / Q000097:blood; D005260:Female; D005838:Genotype; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009020:Morphine / Q000008:administration & dosage* / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000378:metabolism*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000378:metabolism / Q000473:pathology; D000099052:CRF Receptor, Type 1
chemical_list: D009292:Narcotic Antagonists; D018019:Receptors, Corticotropin-Releasing Hormone; D009270:Naloxone; D000099052:CRF Receptor, Type 1; D009020:Morphine; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone
references.citation: Pharmacol Biochem Behav. 1988 Jun;30(2):483-8
references.pmid: 3174779
references.citation: Neuron. 2008 Jul 10;59(1):11-34
references.pmid: 18614026
references.citation: Biol Psychiatry. 2011 Feb 1;69(3):236-44
references.pmid: 20947067
references.citation: Psychopharmacology (Berl). 2012 Mar;220(2):379-93
references.pmid: 21947312
references.citation: Neuron. 2007 Feb 15;53(4):577-89
references.pmid: 17296558
references.citation: Trends Neurosci. 1992 May;15(5):186-91
references.pmid: 1377426
references.citation: Pharmacol Rep. 2012;64(5):1091-104
references.pmid: 23238466
references.citation: Front Neuroendocrinol. 2008 Jan;29(1):36-47
references.pmid: 17904621
references.citation: Jpn J Pharmacol. 1985 Dec;39(4):453-9
references.pmid: 4094188
references.citation: Neuroscience. 1995 Oct;68(4):969-79
references.pmid: 8545003
references.citation: Brain Res. 2010 Feb 16;1314:130-8
references.pmid: 19699189
references.citation: Biol Psychiatry. 2010 Jan 1;67(1):85-7
references.pmid: 19782965
references.citation: Trends Pharmacol Sci. 2004 May;25(5):273-9
references.pmid: 15120494
references.citation: Behav Brain Res. 2007 Jul 19;181(1):118-26
references.pmid: 17498818
references.citation: Psychopharmacology (Berl). 2013 May;227(1):117-26
references.pmid: 23254375
references.citation: Behav Brain Res. 2012 Mar 1;228(1):144-50
references.pmid: 22178315
references.citation: Psychopharmacology (Berl). 1999 Mar;143(1):1-7
references.pmid: 10227072
references.citation: J Neurochem. 2000 Jan;74(1):199-208
references.pmid: 10617121
references.citation: J Pharmacol Exp Ther. 1969 May;167(1):1-8
references.pmid: 5814495
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18649-54
references.pmid: 16339307
references.citation: Neuroreport. 2014 Jan 22;25(2):105-9
references.pmid: 24145777
references.citation: Annu Rev Pharmacol Toxicol. 2004;44:525-57
references.pmid: 14744257
references.citation: J Neurosci. 2010 Aug 4;30(31):10526-33
references.pmid: 20685995
references.citation: Br J Pharmacol. 2014 Feb;171(3):688-700
references.pmid: 24490859
references.citation: Pharmacol Biochem Behav. 2001 Sep;70(1):149-56
references.pmid: 11566152
references.citation: Neurochem Int. 2012 Aug;61(3):433-40
references.pmid: 22713675
references.citation: Biol Psychiatry. 2009 Jul 15;66(2):110-7
references.pmid: 19217073
references.citation: Behav Pharmacol. 2001 Feb;12(1):75-9
references.pmid: 11270515
references.citation: Drug Discov Ther. 2011 Apr;5(2):71-5
references.pmid: 22466143
references.citation: Psychopharmacology (Berl). 2014 Dec;231(24):4659-68
references.pmid: 24825609
references.citation: Psychoneuroendocrinology. 1995;20(8):789-819
references.pmid: 8834089
references.citation: Brain Res. 2006 Feb 9;1072(1):46-54
references.pmid: 16423327
references.citation: Behav Brain Res. 2006 Jun 3;170(1):110-8
references.pmid: 16580078
references.citation: Life Sci. 1993;52(12):1039-44
references.pmid: 8383266
references.citation: Brain Res. 2010 Feb 16;1314:3-14
references.pmid: 19912996
references.citation: Psychopharmacology (Berl). 2009 Dec;207(2):245-55
references.pmid: 19787337
references.citation: Pain. 2006 Apr;121(3):232-40
references.pmid: 16516386
references.citation: Behav Brain Res. 2007 Jan 25;176(2):251-8
references.pmid: 17123639
references.citation: Neurobiol Learn Mem. 2007 Nov;88(4):435-44
references.pmid: 17613253
references.citation: Exp Clin Psychopharmacol. 2006 Feb;14(1):68-78
references.pmid: 16503706
references.citation: Alcohol Clin Exp Res. 2001 Nov;25(11):1689-96
references.pmid: 11707644
references.citation: Psychopharmacology (Berl). 1996 Jan;123(2):119-26
references.pmid: 8741934
references.citation: Rev Neurosci. 1993 Oct-Dec;4(4):397-405
references.pmid: 8275278
references.citation: Horm Behav. 2010 Jun;58(1):44-56
references.pmid: 19818789
references.citation: Trends Endocrinol Metab. 2008 Jul;19(5):175-80
references.pmid: 18394919
references.citation: Neuropsychopharmacology. 2012 Oct;37(11):2405-15
references.pmid: 22692565
references.citation: Curr Top Behav Neurosci. 2011;8:73-96
references.pmid: 21769724
references.citation: Pharmacol Biochem Behav. 2002 Jun;72(3):691-7
references.pmid: 12175466
references.citation: Am J Drug Alcohol Abuse. 1976;3(2):363-8
references.pmid: 1036445
references.citation: J Stud Alcohol. 2003 May;64(3):375-9
references.pmid: 12817826
references.citation: Mol Pharmacol. 2010 May;77(5):864-73
references.pmid: 20159948
references.citation: Gen Pharmacol. 1994 Nov;25(7):1505-10
references.pmid: 7896067
references.citation: Addict Biol. 2007 Sep;12(3-4):227-462
references.pmid: 17678505
references.citation: Neurobiol Learn Mem. 2008 May;89(4):504-12
references.pmid: 17905604
references.citation: J Neurosci. 2007 Feb 21;27(8):2025-34
references.pmid: 17314298